A new study indicates that GlaxoSmithKline's cervical cancer vaccine Cervarix appears to have a heightened response among girls aged 10 to 14. Researchers say this could mean that younger girls who are vaccinated may have a lower need for booster shots later in life. Cervarix has been shown to target two viruses that account for 70 percent of all cases of cervical cancer.
- read this report [1] from the Independent for more
Links:
[1] http://news.independent.co.uk/uk/health_medical/article333953.ece